Source - LSE Non-Regulatory
RNS Number : 4197B
Nuformix PLC
02 June 2023
 

REACH

 

2 June 2023

 

Nuformix plc

 

("Nuformix" or the "Company" or the "Group")

 

Investor Online Q&A

 

Nuformix plc (LSE: NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, is pleased to announce that the Company's Executive Director, Dr Dan Gooding, will be hosting an online Q&A session at 5.30 p.m. GMT on Tuesday 13 June 2023.  This session is open to all existing and prospective shareholders.  Those who wish to attend should register via the following link where they will be provided with access details:

 

https://us02web.zoom.us/webinar/register/WN_fV_2UztcQLSl1S1tC4vTGg

 

Participants will have the opportunity to submit questions during the session, but questions are welcomed in advance and may be submitted to: nuformix@investor-focus.co.uk

 

Enquiries:

 

Nuformix plc

 

Dr Dan Gooding, Executive Director

 

Via IFC Advisory

 

Stanford Capital Partners Limited

 

Tom Price / Patrick Claridge (Corporate Finance)

+44 (0) 20 3650 3650

John Howes / Bob Pountney (Corporate Broking)

+44 (0) 20 3650 3652

 

IFC Advisory Limited

 

Tim Metcalfe

Zach Cohen

+44 (0) 20 3934 6630

nuformix@investor-focus.co.uk

 

About Nuformix

 

Nuformix is a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing. The Company aims to use its expertise in discovering, developing and patenting novel drug forms, with improved physical properties, to develop new products in new indications that are, importantly, differentiated from the original (by way of dosage, delivery route or presentation), thus creating new and attractive commercial opportunities. Nuformix has a pipeline of pre-clinical assets with potential for significant value and early licensing opportunities.

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRAUAUWROBUNRAR
Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account. AJ Bell logo

Related Charts

Nuformix PLC (NFX)

0p (0.00%)
delayed 16:30PM